PMC:7195088 / 42615-44426 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1203","span":{"begin":982,"end":985},"obj":"Gene"},{"id":"1204","span":{"begin":567,"end":575},"obj":"Species"},{"id":"1205","span":{"begin":1105,"end":1113},"obj":"Species"},{"id":"1206","span":{"begin":1288,"end":1314},"obj":"Species"},{"id":"1207","span":{"begin":1514,"end":1522},"obj":"Species"},{"id":"1208","span":{"begin":84,"end":97},"obj":"Chemical"},{"id":"1209","span":{"begin":1361,"end":1372},"obj":"Chemical"},{"id":"1210","span":{"begin":30,"end":63},"obj":"Disease"},{"id":"1211","span":{"begin":152,"end":161},"obj":"Disease"},{"id":"1212","span":{"begin":245,"end":251},"obj":"Disease"},{"id":"1213","span":{"begin":262,"end":295},"obj":"Disease"},{"id":"1214","span":{"begin":304,"end":318},"obj":"Disease"},{"id":"1215","span":{"begin":347,"end":354},"obj":"Disease"},{"id":"1216","span":{"begin":409,"end":417},"obj":"Disease"},{"id":"1217","span":{"begin":427,"end":436},"obj":"Disease"},{"id":"1218","span":{"begin":445,"end":456},"obj":"Disease"},{"id":"1219","span":{"begin":477,"end":484},"obj":"Disease"},{"id":"1220","span":{"begin":492,"end":500},"obj":"Disease"},{"id":"1221","span":{"begin":540,"end":551},"obj":"Disease"},{"id":"1222","span":{"begin":634,"end":658},"obj":"Disease"},{"id":"1223","span":{"begin":660,"end":674},"obj":"Disease"},{"id":"1224","span":{"begin":676,"end":685},"obj":"Disease"},{"id":"1225","span":{"begin":687,"end":693},"obj":"Disease"},{"id":"1226","span":{"begin":695,"end":703},"obj":"Disease"},{"id":"1227","span":{"begin":705,"end":720},"obj":"Disease"},{"id":"1228","span":{"begin":722,"end":732},"obj":"Disease"},{"id":"1229","span":{"begin":734,"end":750},"obj":"Disease"},{"id":"1230","span":{"begin":807,"end":815},"obj":"Disease"},{"id":"1231","span":{"begin":817,"end":829},"obj":"Disease"},{"id":"1232","span":{"begin":1065,"end":1076},"obj":"Disease"},{"id":"1233","span":{"begin":1117,"end":1125},"obj":"Disease"},{"id":"1234","span":{"begin":1135,"end":1147},"obj":"Disease"},{"id":"1235","span":{"begin":1157,"end":1166},"obj":"Disease"},{"id":"1236","span":{"begin":1174,"end":1188},"obj":"Disease"},{"id":"1237","span":{"begin":1197,"end":1211},"obj":"Disease"},{"id":"1238","span":{"begin":1234,"end":1248},"obj":"Disease"},{"id":"1239","span":{"begin":1256,"end":1266},"obj":"Disease"},{"id":"1240","span":{"begin":1274,"end":1286},"obj":"Disease"},{"id":"1241","span":{"begin":1589,"end":1597},"obj":"Disease"},{"id":"1242","span":{"begin":1602,"end":1610},"obj":"Disease"},{"id":"1243","span":{"begin":1622,"end":1632},"obj":"Disease"},{"id":"1244","span":{"begin":1644,"end":1649},"obj":"Disease"},{"id":"1245","span":{"begin":1661,"end":1682},"obj":"Disease"},{"id":"1246","span":{"begin":1693,"end":1705},"obj":"Disease"},{"id":"1247","span":{"begin":1707,"end":1717},"obj":"Disease"},{"id":"1248","span":{"begin":1756,"end":1762},"obj":"Disease"},{"id":"1249","span":{"begin":1767,"end":1776},"obj":"Disease"}],"attributes":[{"id":"A1203","pred":"tao:has_database_id","subj":"1203","obj":"Gene:26503"},{"id":"A1204","pred":"tao:has_database_id","subj":"1204","obj":"Tax:9606"},{"id":"A1205","pred":"tao:has_database_id","subj":"1205","obj":"Tax:9606"},{"id":"A1206","pred":"tao:has_database_id","subj":"1206","obj":"Tax:1773"},{"id":"A1207","pred":"tao:has_database_id","subj":"1207","obj":"Tax:9606"},{"id":"A1208","pred":"tao:has_database_id","subj":"1208","obj":"MESH:D014280"},{"id":"A1209","pred":"tao:has_database_id","subj":"1209","obj":"MESH:C502936"},{"id":"A1210","pred":"tao:has_database_id","subj":"1210","obj":"MESH:C564286"},{"id":"A1211","pred":"tao:has_database_id","subj":"1211","obj":"MESH:D003967"},{"id":"A1212","pred":"tao:has_database_id","subj":"1212","obj":"MESH:D009325"},{"id":"A1213","pred":"tao:has_database_id","subj":"1213","obj":"MESH:D012141"},{"id":"A1214","pred":"tao:has_database_id","subj":"1214","obj":"MESH:D015746"},{"id":"A1215","pred":"tao:has_database_id","subj":"1215","obj":"MESH:D005221"},{"id":"A1216","pred":"tao:has_database_id","subj":"1216","obj":"MESH:D006261"},{"id":"A1217","pred":"tao:has_database_id","subj":"1217","obj":"MESH:D005076"},{"id":"A1218","pred":"tao:has_database_id","subj":"1218","obj":"MESH:D009503"},{"id":"A1219","pred":"tao:has_database_id","subj":"1219","obj":"MESH:D001007"},{"id":"A1220","pred":"tao:has_database_id","subj":"1220","obj":"MESH:D007319"},{"id":"A1221","pred":"tao:has_database_id","subj":"1221","obj":"MESH:D012164"},{"id":"A1222","pred":"tao:has_database_id","subj":"1222","obj":"MESH:D013262"},{"id":"A1223","pred":"tao:has_database_id","subj":"1223","obj":"MESH:D015746"},{"id":"A1224","pred":"tao:has_database_id","subj":"1224","obj":"MESH:D003967"},{"id":"A1225","pred":"tao:has_database_id","subj":"1225","obj":"MESH:D009325"},{"id":"A1226","pred":"tao:has_database_id","subj":"1226","obj":"MESH:D014839"},{"id":"A1227","pred":"tao:has_database_id","subj":"1227","obj":"MESH:D000380"},{"id":"A1228","pred":"tao:has_database_id","subj":"1228","obj":"MESH:D007970"},{"id":"A1229","pred":"tao:has_database_id","subj":"1229","obj":"MESH:D013921"},{"id":"A1230","pred":"tao:has_database_id","subj":"1230","obj":"MESH:D009135"},{"id":"A1231","pred":"tao:has_database_id","subj":"1231","obj":"MESH:D001986"},{"id":"A1232","pred":"tao:has_database_id","subj":"1232","obj":"MESH:D009503"},{"id":"A1233","pred":"tao:has_database_id","subj":"1233","obj":"MESH:D006261"},{"id":"A1234","pred":"tao:has_database_id","subj":"1234","obj":"MESH:D006973"},{"id":"A1235","pred":"tao:has_database_id","subj":"1235","obj":"MESH:D004244"},{"id":"A1236","pred":"tao:has_database_id","subj":"1236","obj":"MESH:D007037"},{"id":"A1237","pred":"tao:has_database_id","subj":"1237","obj":"MESH:D015746"},{"id":"A1238","pred":"tao:has_database_id","subj":"1238","obj":"MESH:D013276"},{"id":"A1239","pred":"tao:has_database_id","subj":"1239","obj":"MESH:D007239"},{"id":"A1240","pred":"tao:has_database_id","subj":"1240","obj":"MESH:D011020"},{"id":"A1241","pred":"tao:has_database_id","subj":"1241","obj":"MESH:D006261"},{"id":"A1242","pred":"tao:has_database_id","subj":"1242","obj":"MESH:D014839"},{"id":"A1243","pred":"tao:has_database_id","subj":"1243","obj":"MESH:D018771"},{"id":"A1244","pred":"tao:has_database_id","subj":"1244","obj":"MESH:D005334"},{"id":"A1245","pred":"tao:has_database_id","subj":"1245","obj":"MESH:D006402"},{"id":"A1246","pred":"tao:has_database_id","subj":"1246","obj":"MESH:D004802"},{"id":"A1247","pred":"tao:has_database_id","subj":"1247","obj":"MESH:D007970"},{"id":"A1248","pred":"tao:has_database_id","subj":"1248","obj":"MESH:D009325"},{"id":"A1249","pred":"tao:has_database_id","subj":"1249","obj":"MESH:D003967"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T65","span":{"begin":78,"end":83},"obj":"Body_part"},{"id":"T66","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T67","span":{"begin":262,"end":285},"obj":"Body_part"},{"id":"T68","span":{"begin":372,"end":377},"obj":"Body_part"},{"id":"T69","span":{"begin":427,"end":431},"obj":"Body_part"},{"id":"T70","span":{"begin":961,"end":966},"obj":"Body_part"},{"id":"T71","span":{"begin":1005,"end":1008},"obj":"Body_part"},{"id":"T72","span":{"begin":1219,"end":1230},"obj":"Body_part"},{"id":"T73","span":{"begin":1224,"end":1230},"obj":"Body_part"},{"id":"T74","span":{"begin":1475,"end":1483},"obj":"Body_part"},{"id":"T75","span":{"begin":1545,"end":1553},"obj":"Body_part"},{"id":"T76","span":{"begin":1732,"end":1740},"obj":"Body_part"}],"attributes":[{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma45661"},{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A69","pred":"fma_id","subj":"T69","obj":"http://purl.org/sig/ont/fma/fma7163"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma63170"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma59660"},{"id":"A73","pred":"fma_id","subj":"T73","obj":"http://purl.org/sig/ont/fma/fma85355"},{"id":"A74","pred":"fma_id","subj":"T74","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A76","pred":"fma_id","subj":"T76","obj":"http://purl.org/sig/ont/fma/fma62851"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T36","span":{"begin":78,"end":83},"obj":"Body_part"},{"id":"T37","span":{"begin":214,"end":219},"obj":"Body_part"},{"id":"T38","span":{"begin":262,"end":285},"obj":"Body_part"},{"id":"T39","span":{"begin":268,"end":285},"obj":"Body_part"},{"id":"T40","span":{"begin":372,"end":377},"obj":"Body_part"},{"id":"T41","span":{"begin":427,"end":431},"obj":"Body_part"},{"id":"T42","span":{"begin":961,"end":966},"obj":"Body_part"},{"id":"T43","span":{"begin":1224,"end":1230},"obj":"Body_part"}],"attributes":[{"id":"A36","pred":"uberon_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0001557"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A40","pred":"uberon_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A41","pred":"uberon_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/UBERON_0000014"},{"id":"A42","pred":"uberon_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A43","pred":"uberon_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/UBERON_0000344"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T45","span":{"begin":68,"end":97},"obj":"Phenotype"},{"id":"T46","span":{"begin":152,"end":161},"obj":"Phenotype"},{"id":"T47","span":{"begin":245,"end":251},"obj":"Phenotype"},{"id":"T48","span":{"begin":262,"end":295},"obj":"Phenotype"},{"id":"T49","span":{"begin":304,"end":318},"obj":"Phenotype"},{"id":"T50","span":{"begin":329,"end":337},"obj":"Phenotype"},{"id":"T51","span":{"begin":347,"end":354},"obj":"Phenotype"},{"id":"T52","span":{"begin":409,"end":417},"obj":"Phenotype"},{"id":"T53","span":{"begin":427,"end":436},"obj":"Phenotype"},{"id":"T54","span":{"begin":445,"end":456},"obj":"Phenotype"},{"id":"T55","span":{"begin":477,"end":484},"obj":"Phenotype"},{"id":"T56","span":{"begin":492,"end":500},"obj":"Phenotype"},{"id":"T57","span":{"begin":540,"end":551},"obj":"Phenotype"},{"id":"T58","span":{"begin":660,"end":674},"obj":"Phenotype"},{"id":"T59","span":{"begin":676,"end":685},"obj":"Phenotype"},{"id":"T60","span":{"begin":687,"end":703},"obj":"Phenotype"},{"id":"T61","span":{"begin":705,"end":720},"obj":"Phenotype"},{"id":"T62","span":{"begin":722,"end":732},"obj":"Phenotype"},{"id":"T63","span":{"begin":734,"end":750},"obj":"Phenotype"},{"id":"T64","span":{"begin":785,"end":798},"obj":"Phenotype"},{"id":"T65","span":{"begin":807,"end":815},"obj":"Phenotype"},{"id":"T66","span":{"begin":817,"end":829},"obj":"Phenotype"},{"id":"T67","span":{"begin":840,"end":861},"obj":"Phenotype"},{"id":"T68","span":{"begin":995,"end":1020},"obj":"Phenotype"},{"id":"T69","span":{"begin":1065,"end":1076},"obj":"Phenotype"},{"id":"T70","span":{"begin":1117,"end":1125},"obj":"Phenotype"},{"id":"T71","span":{"begin":1135,"end":1147},"obj":"Phenotype"},{"id":"T72","span":{"begin":1157,"end":1166},"obj":"Phenotype"},{"id":"T73","span":{"begin":1174,"end":1188},"obj":"Phenotype"},{"id":"T74","span":{"begin":1197,"end":1211},"obj":"Phenotype"},{"id":"T75","span":{"begin":1234,"end":1248},"obj":"Phenotype"},{"id":"T76","span":{"begin":1589,"end":1597},"obj":"Phenotype"},{"id":"T77","span":{"begin":1602,"end":1610},"obj":"Phenotype"},{"id":"T78","span":{"begin":1622,"end":1632},"obj":"Phenotype"},{"id":"T79","span":{"begin":1644,"end":1649},"obj":"Phenotype"},{"id":"T80","span":{"begin":1693,"end":1705},"obj":"Phenotype"},{"id":"T81","span":{"begin":1707,"end":1717},"obj":"Phenotype"},{"id":"T82","span":{"begin":1756,"end":1762},"obj":"Phenotype"},{"id":"T83","span":{"begin":1767,"end":1776},"obj":"Phenotype"}],"attributes":[{"id":"A45","pred":"hp_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/HP_0002155"},{"id":"A46","pred":"hp_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A47","pred":"hp_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/HP_0002018"},{"id":"A48","pred":"hp_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/HP_0002788"},{"id":"A49","pred":"hp_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A50","pred":"hp_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A51","pred":"hp_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A52","pred":"hp_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A53","pred":"hp_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/HP_0000988"},{"id":"A54","pred":"hp_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0000739"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0100785"},{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0000488"},{"id":"A58","pred":"hp_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A60","pred":"hp_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A61","pred":"hp_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/HP_0012234"},{"id":"A62","pred":"hp_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A63","pred":"hp_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/HP_0001873"},{"id":"A64","pred":"hp_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/HP_0200119"},{"id":"A65","pred":"hp_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/HP_0003198"},{"id":"A66","pred":"hp_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/HP_0025428"},{"id":"A67","pred":"hp_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/HP_0001657"},{"id":"A68","pred":"hp_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/HP_0003141"},{"id":"A69","pred":"hp_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/HP_0001875"},{"id":"A70","pred":"hp_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A71","pred":"hp_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A72","pred":"hp_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/HP_0002321"},{"id":"A73","pred":"hp_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/HP_0000821"},{"id":"A74","pred":"hp_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A75","pred":"hp_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/HP_0002592"},{"id":"A76","pred":"hp_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A77","pred":"hp_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A78","pred":"hp_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/HP_0002829"},{"id":"A79","pred":"hp_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A80","pred":"hp_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/HP_0001880"},{"id":"A81","pred":"hp_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A82","pred":"hp_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/HP_0002018"},{"id":"A83","pred":"hp_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/HP_0002014"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T210","span":{"begin":152,"end":161},"obj":"Disease"},{"id":"T211","span":{"begin":268,"end":295},"obj":"Disease"},{"id":"T212","span":{"begin":286,"end":295},"obj":"Disease"},{"id":"T213","span":{"begin":427,"end":436},"obj":"Disease"},{"id":"T214","span":{"begin":445,"end":456},"obj":"Disease"},{"id":"T215","span":{"begin":477,"end":484},"obj":"Disease"},{"id":"T217","span":{"begin":492,"end":500},"obj":"Disease"},{"id":"T218","span":{"begin":540,"end":551},"obj":"Disease"},{"id":"T219","span":{"begin":634,"end":658},"obj":"Disease"},{"id":"T220","span":{"begin":642,"end":658},"obj":"Disease"},{"id":"T221","span":{"begin":676,"end":685},"obj":"Disease"},{"id":"T222","span":{"begin":705,"end":720},"obj":"Disease"},{"id":"T223","span":{"begin":722,"end":732},"obj":"Disease"},{"id":"T224","span":{"begin":734,"end":750},"obj":"Disease"},{"id":"T225","span":{"begin":807,"end":815},"obj":"Disease"},{"id":"T226","span":{"begin":817,"end":829},"obj":"Disease"},{"id":"T227","span":{"begin":1065,"end":1076},"obj":"Disease"},{"id":"T228","span":{"begin":1135,"end":1147},"obj":"Disease"},{"id":"T229","span":{"begin":1174,"end":1188},"obj":"Disease"},{"id":"T230","span":{"begin":1234,"end":1248},"obj":"Disease"},{"id":"T231","span":{"begin":1242,"end":1248},"obj":"Disease"},{"id":"T232","span":{"begin":1274,"end":1286},"obj":"Disease"},{"id":"T233","span":{"begin":1302,"end":1314},"obj":"Disease"},{"id":"T234","span":{"begin":1319,"end":1328},"obj":"Disease"},{"id":"T235","span":{"begin":1329,"end":1335},"obj":"Disease"},{"id":"T236","span":{"begin":1693,"end":1705},"obj":"Disease"},{"id":"T237","span":{"begin":1707,"end":1717},"obj":"Disease"},{"id":"T238","span":{"begin":1767,"end":1776},"obj":"Disease"}],"attributes":[{"id":"A210","pred":"mondo_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0024355"},{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A213","pred":"mondo_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/MONDO_0006547"},{"id":"A214","pred":"mondo_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A215","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0005618"},{"id":"A216","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0011918"},{"id":"A217","pred":"mondo_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/MONDO_0013600"},{"id":"A218","pred":"mondo_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/MONDO_0005283"},{"id":"A219","pred":"mondo_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/MONDO_0018229"},{"id":"A220","pred":"mondo_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/MONDO_0019419"},{"id":"A221","pred":"mondo_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A222","pred":"mondo_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/MONDO_0001609"},{"id":"A223","pred":"mondo_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A224","pred":"mondo_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/MONDO_0002049"},{"id":"A225","pred":"mondo_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/MONDO_0005336"},{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0001358"},{"id":"A227","pred":"mondo_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/MONDO_0001475"},{"id":"A228","pred":"mondo_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A229","pred":"mondo_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/MONDO_0005420"},{"id":"A230","pred":"mondo_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/MONDO_0001126"},{"id":"A231","pred":"mondo_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/MONDO_0043839"},{"id":"A232","pred":"mondo_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/MONDO_0019121"},{"id":"A233","pred":"mondo_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"},{"id":"A234","pred":"mondo_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/MONDO_0005700"},{"id":"A235","pred":"mondo_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/MONDO_0005609"},{"id":"A236","pred":"mondo_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/MONDO_0015691"},{"id":"A237","pred":"mondo_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T239","span":{"begin":231,"end":234},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T240","span":{"begin":238,"end":240},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T241","span":{"begin":322,"end":324},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T242","span":{"begin":339,"end":342},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T243","span":{"begin":427,"end":431},"obj":"http://purl.obolibrary.org/obo/UBERON_0000014"},{"id":"T244","span":{"begin":427,"end":431},"obj":"http://purl.obolibrary.org/obo/UBERON_0001003"},{"id":"T245","span":{"begin":427,"end":431},"obj":"http://purl.obolibrary.org/obo/UBERON_0002097"},{"id":"T246","span":{"begin":427,"end":431},"obj":"http://purl.obolibrary.org/obo/UBERON_0002199"},{"id":"T247","span":{"begin":427,"end":431},"obj":"http://www.ebi.ac.uk/efo/EFO_0000962"},{"id":"T248","span":{"begin":464,"end":467},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T249","span":{"begin":576,"end":577},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T250","span":{"begin":778,"end":783},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T251","span":{"begin":973,"end":975},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T252","span":{"begin":988,"end":990},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T253","span":{"begin":1087,"end":1090},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T254","span":{"begin":1224,"end":1230},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"T255","span":{"begin":1395,"end":1398},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T256","span":{"begin":1468,"end":1470},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T528","span":{"begin":20,"end":29},"obj":"Chemical"},{"id":"T529","span":{"begin":30,"end":39},"obj":"Chemical"},{"id":"T530","span":{"begin":84,"end":97},"obj":"Chemical"},{"id":"T531","span":{"begin":120,"end":128},"obj":"Chemical"},{"id":"T532","span":{"begin":507,"end":518},"obj":"Chemical"},{"id":"T533","span":{"begin":519,"end":537},"obj":"Chemical"},{"id":"T534","span":{"begin":924,"end":936},"obj":"Chemical"},{"id":"T535","span":{"begin":982,"end":985},"obj":"Chemical"},{"id":"T536","span":{"begin":1005,"end":1020},"obj":"Chemical"},{"id":"T537","span":{"begin":1005,"end":1008},"obj":"Chemical"},{"id":"T538","span":{"begin":1009,"end":1020},"obj":"Chemical"},{"id":"T539","span":{"begin":1361,"end":1372},"obj":"Chemical"}],"attributes":[{"id":"A528","pred":"chebi_id","subj":"T528","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A529","pred":"chebi_id","subj":"T529","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A530","pred":"chebi_id","subj":"T530","obj":"http://purl.obolibrary.org/obo/CHEBI_17855"},{"id":"A531","pred":"chebi_id","subj":"T531","obj":"http://purl.obolibrary.org/obo/CHEBI_32483"},{"id":"A532","pred":"chebi_id","subj":"T532","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A533","pred":"chebi_id","subj":"T533","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A534","pred":"chebi_id","subj":"T534","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A535","pred":"chebi_id","subj":"T535","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A536","pred":"chebi_id","subj":"T536","obj":"http://purl.obolibrary.org/obo/CHEBI_47774"},{"id":"A537","pred":"chebi_id","subj":"T537","obj":"http://purl.obolibrary.org/obo/CHEBI_39026"},{"id":"A538","pred":"chebi_id","subj":"T538","obj":"http://purl.obolibrary.org/obo/CHEBI_16113"},{"id":"A539","pred":"chebi_id","subj":"T539","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T313","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T314","span":{"begin":20,"end":105},"obj":"Sentence"},{"id":"T315","span":{"begin":106,"end":149},"obj":"Sentence"},{"id":"T316","span":{"begin":150,"end":201},"obj":"Sentence"},{"id":"T317","span":{"begin":202,"end":235},"obj":"Sentence"},{"id":"T318","span":{"begin":236,"end":242},"obj":"Sentence"},{"id":"T319","span":{"begin":243,"end":259},"obj":"Sentence"},{"id":"T320","span":{"begin":260,"end":301},"obj":"Sentence"},{"id":"T321","span":{"begin":302,"end":326},"obj":"Sentence"},{"id":"T322","span":{"begin":327,"end":344},"obj":"Sentence"},{"id":"T323","span":{"begin":345,"end":359},"obj":"Sentence"},{"id":"T324","span":{"begin":360,"end":406},"obj":"Sentence"},{"id":"T325","span":{"begin":407,"end":424},"obj":"Sentence"},{"id":"T326","span":{"begin":425,"end":442},"obj":"Sentence"},{"id":"T327","span":{"begin":443,"end":468},"obj":"Sentence"},{"id":"T328","span":{"begin":469,"end":474},"obj":"Sentence"},{"id":"T329","span":{"begin":475,"end":489},"obj":"Sentence"},{"id":"T330","span":{"begin":490,"end":506},"obj":"Sentence"},{"id":"T331","span":{"begin":507,"end":577},"obj":"Sentence"},{"id":"T332","span":{"begin":578,"end":829},"obj":"Sentence"},{"id":"T333","span":{"begin":830,"end":936},"obj":"Sentence"},{"id":"T334","span":{"begin":937,"end":992},"obj":"Sentence"},{"id":"T335","span":{"begin":993,"end":1028},"obj":"Sentence"},{"id":"T336","span":{"begin":1029,"end":1062},"obj":"Sentence"},{"id":"T337","span":{"begin":1063,"end":1086},"obj":"Sentence"},{"id":"T338","span":{"begin":1087,"end":1114},"obj":"Sentence"},{"id":"T339","span":{"begin":1115,"end":1132},"obj":"Sentence"},{"id":"T340","span":{"begin":1133,"end":1154},"obj":"Sentence"},{"id":"T341","span":{"begin":1155,"end":1171},"obj":"Sentence"},{"id":"T342","span":{"begin":1172,"end":1194},"obj":"Sentence"},{"id":"T343","span":{"begin":1195,"end":1216},"obj":"Sentence"},{"id":"T344","span":{"begin":1217,"end":1253},"obj":"Sentence"},{"id":"T345","span":{"begin":1254,"end":1427},"obj":"Sentence"},{"id":"T346","span":{"begin":1428,"end":1472},"obj":"Sentence"},{"id":"T347","span":{"begin":1473,"end":1586},"obj":"Sentence"},{"id":"T348","span":{"begin":1587,"end":1619},"obj":"Sentence"},{"id":"T349","span":{"begin":1620,"end":1641},"obj":"Sentence"},{"id":"T350","span":{"begin":1642,"end":1658},"obj":"Sentence"},{"id":"T351","span":{"begin":1659,"end":1753},"obj":"Sentence"},{"id":"T352","span":{"begin":1754,"end":1783},"obj":"Sentence"},{"id":"T353","span":{"begin":1784,"end":1811},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Drug Adverse events\nLopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)\n• Increased γ-glutamyl transferase (10–29%)\n• Diarrhoea (7–28%; greater with once-daily dosing)\n• Increased serum ALT (grade 3/4: 1–11%)\n• Nausea (5–16%)\n• Upper respiratory tract infection (14%)\n• Abdominal pain (1–11%)\n• Vomiting (2–7%)\n• Fatigue (8%)\n• Increased serum amylase and/or lipase (3–8%)\n• Headache (2–6%)\n• Skin rash (≤5%)\n• Neutropenia (grade 3/4: 1–5%)\n• Anxiety (4%)\n• Insomnia (≤4%)\nChloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a\n• Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm\n• Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin\nTocilizumab • Increased serum ALT (≤36%) and AST (≤22%)\n• Increased LDL cholesterol (9–10%)\n• Injection site reaction (4–10%)\n• Neutropenia (grade 3: 2–7% of all adult patients)\n• Headache (1–7%)\n• Hypertension (1–6%)\n• Dizziness (3%)\n• Hypothyroidism (\u003c2%)\n• Abdominal pain (2%)\n• Oral mucosa or gastric ulcers (2%)\n• Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established\nAnakinra • Injection site reactionb (24–71%)\n• Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)\n• Headache and vomiting (12–14%)\n• Arthralgia (10–12%)\n• Fever (10–12%)\n• Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)\n• Nausea and diarrhoea (7–8%)\n• Serious infectionc (2–3%)"}